Study identifier:D1690L00149
ClinicalTrials.gov identifier:NCT06327815
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients with T2DM: A 24-Week, Multicentre, Randomized, Parallel, Interventional, Non-inferiority, Open-label Study
Type 2 Diabetes Mellitus (T2DM)
Phase 4
No
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, Dapagliflozin tablets and Metformin HCl extended-release tablets
All
632
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: Co-administered Dual Therapy Dapagliflozin tablets and Metformin HCl extended-release tablets | Drug: Dapagliflozin tablets and Metformin HCl extended-release tablets Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg Other Name: Co-administered Dual Therapy |
Experimental: FDC Regimen of Dapagliflozin/Metformin XR Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets | Drug: Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets 10 mg Dapagliflozin/1000 mg Metformin HCl extended-release Other Name: FDC Regimen of Dapagliflozin/Metformin XR |